One of the unintended consequences of the rise of cancer immunotherapy has been the fall in interest from patients who might be candidates for entry into clinical trials for other therapies, such as chemotherapy and targeted agents, for example.
A number of industry friends have uniformally expressed concern over how difficult it has been enroll such trials and bemoaned the broader – and often not anticipated – effect to the extent that some trials have even been terminated.
This situation often occurs, not because of lack of efficacy or severe side effects, but simply a lack of enthusiasm and low accrual rates. Quite a few patients consider chemo to be nothing short of ‘poison’ and don’t want anything to do with it as a result, unless it can be avoided.
Here’s my advice to those in this situation – stop moaning, start re-thinking, and re-positioning your agent in a different light to the investigators who enroll these studies. If they lack heart, in a highly competitive world, you have to stand out and thus, everything flows from the basic rationale of what you’re trying to accomplish.
What exactly do we mean by that?
Yesterday, we discussed one of the rate limiting steps in the cancer immunity cycle – getting more T cells into the tumours so that that subsequent immunotherapy can be even more effective.
One way to do that?
At AACR recently, we came across some intriguing ideas and approaches that are being discussed and explored, which may open many people’s eyes and minds. It rapidly became clear during discussions with several experts that all is not what it seems, and smart companies are already taking advantage of the new science that is emerging as well as a deeper understanding of the underlying biology of how the immune system behaves in cancer patients.
Here, we offer insights from our latest interview with a thought leader in the field for his perspective on how we can improve response rates and outcomes with cancer immunotherapy.
Fair warning: I must confess that it opened my own mind to fresh ideas and different approaches in an unexpected way – you may experience the same sentiments.
To learn more, subscribers can log-in below or you can purchase a subscription…